{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:36:16Z","timestamp":1793111776007,"version":"4.5.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To evaluate whether obese women need greater doses of magnesium sulfate to obtain therapeutic serum concentrations for eclamptic seizure prevention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>Women with preeclampsia and a body mass index (BMI) of 35 or higher were randomly allocated to either the Zuspan regimen of magnesium sulfate (4-g intravenous [IV] loading dose, then a 1-g\/h infusion) or to alternate dosing (6-g IV loading dose, then a 2-g\/h infusion). Women had serum magnesium concentrations obtained at baseline, as well as after administration of magnesium sulfate at 1 hour, 4 hours, and delivery. The primary outcome was the proportion of women who had subtherapeutic serum magnesium concentrations (less than 4.8 mg\/dL) 4 hours after administration. A sample size of 18 women per group was planned to compare the proportion of women with subtherapeutic serum magnesium concentrations in each group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      From July 12, 2016, to March 14, 2019, 89 women with preeclampsia were screened and 37 were enrolled: 18 to the Zuspan regimen and 19 to the alternate regimen. A significantly greater proportion of women administered the Zuspan regimen had subtherapeutic serum magnesium concentrations at 4 hours (100% [95% CI 59\u2013100] vs 63% [95% CI 41\u201381];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =.01) compared with women administered the alternate higher dose regimen. At 4 hours, mean concentrations were significantly higher in the alternate regimen group (3.53 mg\/dL\u00b10.3 [Zuspan regimen] vs 4.41\u00b10.5 [alternate regimen];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>The alternate dosing regimen of a 6-g IV loading dose followed by a 2-g\/h IV maintenance dose more reliably achieves therapeutic serum magnesium concentrations (as defined by a concentration of at least 4.8 mg\/dL) in obese women with preeclampsia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CLINICAL TRIAL REGISTRATION:<\/jats:title>\n                    <jats:p>ClinicalTrials.gov, NCT02835339.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000004137","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T18:01:04Z","timestamp":1604599264000},"page":"1190-1194","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":19,"title":["Alternate Dosing Protocol for Magnesium Sulfate in Obese Women With Preeclampsia"],"prefix":"10.1097","volume":"136","author":[{"given":"Kathleen F.","family":"Brookfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kierstyn","family":"Tuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Rincon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbie","family":"Vinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron B.","family":"Caughey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,11,4]]},"reference":[{"key":"R1-20261027","first-page":"131","article-title":"The use of the magnesium ion in the management of eclamptogenic toxemias","volume":"100","author":"Pritchard","year":"1955","journal-title":"Surg Gyn Obstet"},{"key":"R2-20261027","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0039-6109(16)35131-3","article-title":"Plasma levels of magnesium attained in magnesium therapy for preeclampsia and eclampsia","volume":"37","author":"Chesley","year":"1957","journal-title":"Surg Clin North Am"},{"key":"R3-20261027","first-page":"199","article-title":"Reassessment of intravenous MgSO4 therapy in preeclampsia-eclampsia","volume":"57","author":"Sibai","year":"1981","journal-title":"Obstet Gynecol"},{"key":"R4-20261027","doi-asserted-by":"crossref","first-page":"737.e1","DOI":"10.1016\/j.ajog.2015.12.060","article-title":"Pharmacokinetics and placental transfer of magnesium sulfate in pregnant women","volume":"214","author":"Brookfield","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"R5-20261027","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1097\/AOG.0000000000003891","article-title":"Gestational hypertension and preeclampsia. ACOG Practice Bulletin No. 222. American College of Obstetricians and Gynecologists","volume":"135","year":"2020","journal-title":"Obstet Gynecol"},{"key":"R6-20261027","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/AOG.0b013e31827d90cc","article-title":"Effect of maternal body mass index on serum magnesium levels given for seizure prophylaxis","volume":"121","author":"Tudela","year":"2013","journal-title":"Obstet Gynecol"},{"key":"R7-20261027","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/jcph.1328","article-title":"Population pharmacokinetic modeling to evaluate standard magnesium sulfate treatments and alternative dosing regimens for women with preeclampsia","volume":"59","author":"Du","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"R8-20261027","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1002\/jcph.1448","article-title":"Alternative magnesium sulfate dosing regimens for women with preeclampsia: a population pharmacokinetic exposure-response modeling and simulation study","volume":"59","author":"Du","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"R9-20261027","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/1471-0528.13753","article-title":"Clinical pharmacokinetic properties of magnesium sulfate in women with pre-eclampsia and eclampsia","volume":"123","author":"Okusanya","year":"2016","journal-title":"BJOG"},{"key":"R10-20261027","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1067\/mob.2001.116726","article-title":"Population pharmacokinetics of magnesium in preeclampsia","volume":"185","author":"Chuan","year":"2001","journal-title":"Am J Obstet Gynecol"},{"key":"R11-20261027","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.2165\/00003088-200241130-00007","article-title":"Pharmacokinetic-pharmacodynamic modeling of magnesium plasma concentration and blood pressure in preeclamptic women","volume":"41","author":"Lu","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"R12-20261027","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/1471-0528.12222","article-title":"Magnesium sulfate for prevention of eclampsia: are intramuscular and intravenous regimens equivalent? A population pharmacokinetic study","volume":"120","author":"Salinger","year":"2013","journal-title":"BJOG"},{"key":"R13-20261027","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/S0140-6736(02)08778-0","article-title":"Do women with pre-eclampsia, and their babies, benefit from magnesium sulfate? The Magpie Trial: a randomised placebo-controlled trial","volume":"359","year":"2002","journal-title":"Lancet"},{"key":"R14-20261027","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1081\/PRG-120024029","article-title":"The use of standard dose of magnesium sulfate in prophylaxis of eclamptic seizures: do body mass index alterations have any effect on success?","volume":"22","author":"Dayicioglu","year":"2003","journal-title":"Hypertens Pregnancy"},{"key":"R15-20261027","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1111\/1471-0528.14400","article-title":"Clinical practice patterns on the use of magnesium sulphate for treatment of pre-eclampsia and eclampsia: a multi-country survey","volume":"124","author":"Long","year":"2017","journal-title":"BJOG"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000004137","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:00:17Z","timestamp":1793109617000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000004137"}},"subtitle":["A Randomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2020,11,4]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000004137","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,4]]},"assertion":[{"value":"2020-06-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}